Cargando…

Evaluation of the Safety and Efficacy of Selective Retina Therapy Laser Treatment in Patients with Central Serous Chorioretinopathy

PURPOSE: To assess the safety and efficacy of selective retina therapy (SRT) using a Q-switched neodymium-doped yttrium lithium fluoride laser with feedback systems in patients with idiopathic central serous chorioretinopathy (CSC). METHODS: This randomized clinical trial enrolled patients having at...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Jaeryung, Yoon, Chang Ki, Kim, Bo Hee, Yu, Hyeong Gon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Ophthalmological Society 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904406/
https://www.ncbi.nlm.nih.gov/pubmed/33307626
http://dx.doi.org/10.3341/kjo.2020.0112
_version_ 1783654921456844800
author Oh, Jaeryung
Yoon, Chang Ki
Kim, Bo Hee
Yu, Hyeong Gon
author_facet Oh, Jaeryung
Yoon, Chang Ki
Kim, Bo Hee
Yu, Hyeong Gon
author_sort Oh, Jaeryung
collection PubMed
description PURPOSE: To assess the safety and efficacy of selective retina therapy (SRT) using a Q-switched neodymium-doped yttrium lithium fluoride laser with feedback systems in patients with idiopathic central serous chorioretinopathy (CSC). METHODS: This randomized clinical trial enrolled patients having at least 3-month symptom of CSC. From month 3 visit, all subjects in both groups were eligible for SRT retreatment if they showed persistent or recurrent subretinal fluid (SRF). The primary outcome was complete resolution of SRF by optical coherence tomography at 3 months after treatment. The secondary outcomes were changes in SRF, central macular thickness (CMT) and best-corrected visual acuity at the 1-, 3-, and 6-month examinations. RESULTS: Sixty-eight CSC patients were included (SRT, 31; control, 37). After 1 and 3 months, complete resolution of SRF was achieved in 25.8% and 54.8% of SRT group and 17.6% and 35.1% of controls. The differences were not statistically significant (p = 0.424 and p = 0.142, respectively). However, mixed model for repeated measures analyses showed that the reduction of SRF and CMT were observed earlier in SRT group than in the sham group (least squares mean difference, −59.7 μm; 95% confidence interval, −98.2 to −21.2; p = 0.0029; least squares mean difference −67.0 μm; 95% confidence interval, −104.8 to −29.2; p = 0.0007, respectively). Significant reduction of SRF (≥50% reduction from baseline) was more frequently observed in SRT group (80.6%) than the sham group (44.1%) at month 1 (p = 0.007). Early reduction of SRF and CMT was more abundant in SRT group with symptom duration less than 6 months. Treatment related serious adverse events were not observed. CONCLUSIONS: SRT using a Q-switched neodymium-doped yttrium lithium fluoride laser with feedback system was safe in this trial and effective for early resolution of SRF in the CSC patients. Early intervention with SRT can be a safe alternative for patients with acute symptomatic CSC.
format Online
Article
Text
id pubmed-7904406
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Korean Ophthalmological Society
record_format MEDLINE/PubMed
spelling pubmed-79044062021-03-03 Evaluation of the Safety and Efficacy of Selective Retina Therapy Laser Treatment in Patients with Central Serous Chorioretinopathy Oh, Jaeryung Yoon, Chang Ki Kim, Bo Hee Yu, Hyeong Gon Korean J Ophthalmol Original Article PURPOSE: To assess the safety and efficacy of selective retina therapy (SRT) using a Q-switched neodymium-doped yttrium lithium fluoride laser with feedback systems in patients with idiopathic central serous chorioretinopathy (CSC). METHODS: This randomized clinical trial enrolled patients having at least 3-month symptom of CSC. From month 3 visit, all subjects in both groups were eligible for SRT retreatment if they showed persistent or recurrent subretinal fluid (SRF). The primary outcome was complete resolution of SRF by optical coherence tomography at 3 months after treatment. The secondary outcomes were changes in SRF, central macular thickness (CMT) and best-corrected visual acuity at the 1-, 3-, and 6-month examinations. RESULTS: Sixty-eight CSC patients were included (SRT, 31; control, 37). After 1 and 3 months, complete resolution of SRF was achieved in 25.8% and 54.8% of SRT group and 17.6% and 35.1% of controls. The differences were not statistically significant (p = 0.424 and p = 0.142, respectively). However, mixed model for repeated measures analyses showed that the reduction of SRF and CMT were observed earlier in SRT group than in the sham group (least squares mean difference, −59.7 μm; 95% confidence interval, −98.2 to −21.2; p = 0.0029; least squares mean difference −67.0 μm; 95% confidence interval, −104.8 to −29.2; p = 0.0007, respectively). Significant reduction of SRF (≥50% reduction from baseline) was more frequently observed in SRT group (80.6%) than the sham group (44.1%) at month 1 (p = 0.007). Early reduction of SRF and CMT was more abundant in SRT group with symptom duration less than 6 months. Treatment related serious adverse events were not observed. CONCLUSIONS: SRT using a Q-switched neodymium-doped yttrium lithium fluoride laser with feedback system was safe in this trial and effective for early resolution of SRF in the CSC patients. Early intervention with SRT can be a safe alternative for patients with acute symptomatic CSC. Korean Ophthalmological Society 2021-02 2021-02-05 /pmc/articles/PMC7904406/ /pubmed/33307626 http://dx.doi.org/10.3341/kjo.2020.0112 Text en © 2021 The Korean Ophthalmological Society https://creativecommons.org/licenses/by-nc/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Oh, Jaeryung
Yoon, Chang Ki
Kim, Bo Hee
Yu, Hyeong Gon
Evaluation of the Safety and Efficacy of Selective Retina Therapy Laser Treatment in Patients with Central Serous Chorioretinopathy
title Evaluation of the Safety and Efficacy of Selective Retina Therapy Laser Treatment in Patients with Central Serous Chorioretinopathy
title_full Evaluation of the Safety and Efficacy of Selective Retina Therapy Laser Treatment in Patients with Central Serous Chorioretinopathy
title_fullStr Evaluation of the Safety and Efficacy of Selective Retina Therapy Laser Treatment in Patients with Central Serous Chorioretinopathy
title_full_unstemmed Evaluation of the Safety and Efficacy of Selective Retina Therapy Laser Treatment in Patients with Central Serous Chorioretinopathy
title_short Evaluation of the Safety and Efficacy of Selective Retina Therapy Laser Treatment in Patients with Central Serous Chorioretinopathy
title_sort evaluation of the safety and efficacy of selective retina therapy laser treatment in patients with central serous chorioretinopathy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904406/
https://www.ncbi.nlm.nih.gov/pubmed/33307626
http://dx.doi.org/10.3341/kjo.2020.0112
work_keys_str_mv AT ohjaeryung evaluationofthesafetyandefficacyofselectiveretinatherapylasertreatmentinpatientswithcentralserouschorioretinopathy
AT yoonchangki evaluationofthesafetyandefficacyofselectiveretinatherapylasertreatmentinpatientswithcentralserouschorioretinopathy
AT kimbohee evaluationofthesafetyandefficacyofselectiveretinatherapylasertreatmentinpatientswithcentralserouschorioretinopathy
AT yuhyeonggon evaluationofthesafetyandefficacyofselectiveretinatherapylasertreatmentinpatientswithcentralserouschorioretinopathy